Table 4 |
|||||||||||
|
Particle-induced Antibody Formation |
|||||||||||
|
Particle Preparations |
|||||||||||
|
Expt. |
Virus |
Modification |
Relative Optical Density Units |
||||||||
|
|
|||||||||||
|
1. |
HSV-1 Coated |
HSV-2 Coated |
HIV-1 Coated |
||||||||
|
|
|||||||||||
|
9D |
13D |
16D |
9D |
13D |
16D |
9, 13, 16 Days |
|||||
|
|
|||||||||||
|
None |
None |
0.089 |
0.034 |
0.02 |
0.006 |
0.006 |
0.005 |
0.006 |
|||
|
HSV-2 |
non-engineered |
0.050 |
0.019 |
0.010 |
0.006 |
0.006 |
0.005 |
0.005 |
|||
|
B7-engineered |
3.6 |
16.5 |
7.9 |
0.2 |
0.3 |
0.3 |
0.004 |
||||
|
B7+antiCD3 |
3.7 |
3.7 |
6.8 |
0.3 |
0.4 |
0.7 |
0.005 |
||||
|
|
|||||||||||
|
2. |
HSV-1 Coated |
HSV-2 Coated |
HIV-1 or VSV Coated |
||||||||
|
|
|||||||||||
|
3D |
6D |
10D |
3D |
6D |
10D |
3D |
6D |
10D |
|||
|
None |
None |
0.007 |
0.005 |
0.005 |
0.005 |
0.005 |
0.005 |
0.005 |
0.005 |
0.063 |
|
|
PHA/IL-2 |
0.005 |
0.012 |
0.7 |
0.005 |
0.004 |
0.1 |
0.007 |
0.007 |
0.005 |
||
|
HSV-2 |
non-engineered |
0.002 |
1.4 |
5.2 |
0.008 |
1.3 |
0.8 |
0.003 |
0.003 |
0.001 |
|
|
antiCD3 |
0.2 |
1.9 |
10.0 |
0.2 |
1.7 |
3.0 |
0.003 |
0.004 |
0.005 |
||
|
B7-engineered |
0.001 |
0.9 |
7.5 |
0.003 |
0.7 |
1.5 |
0.003 |
0.008 |
0.004 |
||
|
B7+antiCD3 |
0.001 |
1.3 |
6.5 |
0.025 |
1.2 |
7.3 |
0,004 |
0.005 |
0.004 |
||
|
HIV-1 |
non-engineered |
0.002 |
0.006 |
0.006 |
0.004 |
0.019 |
0.004 |
0.004 |
0.004 |
0.004 |
|
|
B7-engineered |
0.001 |
0.008 |
0.023 |
0.004 |
0.004 |
0.021 |
0.004 |
0.003 |
0.002 |
||
|
B7+antiCD3 |
0.008 |
0.007 |
0.031 |
0.004 |
0.004 |
0.027 |
0.006 |
0.001 |
0.005 |
||
|
|
|||||||||||
|
3. |
Influenza-A Japan Coated |
Influenza-B Taiwan Coated |
Influenza-B Russian Coated |
||||||||
|
|
|||||||||||
|
11D |
15D |
11D |
15D |
11D |
15D |
||||||
|
|
|||||||||||
|
None |
None |
0.016 |
0.030 |
0.005 |
0.037 |
0.006 |
0.007 |
||||
|
PHA/IL-2 |
0.16 |
0.030 |
0.010 |
0.046 |
0.018 |
0.007 |
|||||
|
Influenza-A |
non-engineered |
0.010 |
0.005 |
0.010 |
0.046 |
0.018 |
0.007 |
||||
|
Japan |
antiCD3 |
0.014 |
0.004 |
0.22 |
0.29 |
0.21 |
0.15 |
||||
|
B7-engineered |
0.011 |
0.004 |
0.008 |
0.006 |
0.014 |
0.005 |
|||||
|
B7+antiCD3 |
0.012 |
0.006 |
0.009 |
0.011 |
0.023 |
0.006 |
|||||
|
Influenza-A |
non-engineered |
0.013 |
0.004 |
0.006 |
0.005 |
0.003 |
0.004 |
||||
|
PR8 |
antiCD3 |
0.009 |
0.004 |
0.010 |
0.008 |
0.15 |
0.16 |
||||
|
B7-engineered |
0.40 |
0.34 |
0.004 |
0.004 |
0.017 |
0.011 |
|||||
|
B7+antiCD3 |
0.10 |
0.031 |
0.008 |
0.004 |
0.009 |
0.003 |
|||||
|
Influenza-B |
non-engineered |
0.013 |
0.004 |
0.004 |
0.004 |
0.003 |
0.005 |
||||
|
Taiwan |
antiCD3 |
0.010 |
0.007 |
0.008 |
0.005 |
0.007 |
0.004 |
||||
|
B7-engineered |
0.16 |
0.09 |
0.005 |
0.004 |
0.004 |
0.004 |
|||||
|
B7+antiCD3 |
0.011 |
0.002 |
0.005 |
0.005 |
0.007 |
0.003 |
|||||
|
|
|||||||||||
|
Mosca et al. Retrovirology 2007 4:32 doi:10.1186/1742-4690-4-32 |
|||||||||||
